HUE066474T2 - BCMA-specifitással rendelkezõ kiméra antigénreceptorok és azok alkalmazása - Google Patents

BCMA-specifitással rendelkezõ kiméra antigénreceptorok és azok alkalmazása

Info

Publication number: HUE066474T2
Authority: HU; Hungary
Prior art keywords: application; chimeric antigen; antigen receptors; bcma specificity; bcma
Prior art date: 2018-07-19

Application number

HUE19749097A

Other languages

English (en)

Inventor

David Dilillo

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-07-19

Filing date

2019-07-18

Publication date

2024-08-28

2019-07-18 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2024-08-28 Publication of HUE066474T2 publication Critical patent/HUE066474T2/hu

Links

BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Mycology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

HUE19749097A 2018-07-19 2019-07-18 BCMA-specifitással rendelkezõ kiméra antigénreceptorok és azok alkalmazása HUE066474T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201862700615P	2018-07-19	2018-07-19

Publications (1)

Publication Number	Publication Date
HUE066474T2 true HUE066474T2 (hu)	2024-08-28

Family

ID=67515170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE19749097A HUE066474T2 (hu)	2018-07-19	2019-07-18	BCMA-specifitással rendelkezõ kiméra antigénreceptorok és azok alkalmazása

Country Status (30)

Country	Link
US (2)	US12150959B2 (hu)
EP (2)	EP3823665B1 (hu)
JP (2)	JP7404335B2 (hu)
CN (2)	CN119954969A (hu)
AU (1)	AU2019308290B2 (hu)
BR (1)	BR112021000919A2 (hu)
CA (1)	CA3106612A1 (hu)
CL (2)	CL2021000142A1 (hu)
CO (1)	CO2021000334A2 (hu)
DK (2)	DK3823665T5 (hu)
EA (1)	EA202190315A1 (hu)
ES (2)	ES3042810T3 (hu)
FI (2)	FI3823665T3 (hu)
HR (2)	HRP20251331T1 (hu)
HU (1)	HUE066474T2 (hu)
IL (1)	IL279979A (hu)
LT (2)	LT3823665T (hu)
MA (1)	MA65527B1 (hu)
MD (1)	MD3823665T2 (hu)
MX (3)	MX2021000532A (hu)
MY (1)	MY207197A (hu)
PH (1)	PH12021550036A1 (hu)
PL (1)	PL3823665T3 (hu)
PT (2)	PT3823665T (hu)
RS (2)	RS65384B1 (hu)
SG (1)	SG11202100221VA (hu)
SI (1)	SI3823665T1 (hu)
SM (2)	SMT202400102T1 (hu)
WO (1)	WO2020018825A1 (hu)
ZA (1)	ZA202100107B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119752801A (zh)	2018-08-01	2025-04-04	南克维斯特公司	用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
HUE069503T2 (hu)	2018-09-27	2025-03-28	Autolus Ltd	Kiméra antigénreceptor
US11052112B2 (en)	2019-05-30	2021-07-06	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-BCMA immunotherapy
MX2022006714A (es) *	2019-12-06	2022-08-08	Regeneron Pharma	Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
US11230699B2 (en)	2020-01-28	2022-01-25	Immunitybio, Inc.	Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
CN115087666B (zh) *	2020-02-13	2023-10-03	北京艺妙神州医药科技有限公司	嵌合抗原受体的优化
US20230346734A1 (en) *	2020-04-14	2023-11-02	Julius-Maximilians-Universität Würzburg	Combination therapy of atra or other retinoids with immunotherapeutic agents binding to bcma
KR102316091B1 (ko) *	2020-06-17	2021-10-25	국립암센터	Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
CN112812186B (zh) *	2021-02-08	2022-07-29	华道(上海)生物医药有限公司	一种抗b细胞成熟抗原的纳米抗体及其应用
CN113109572A (zh) *	2021-04-01	2021-07-13	苏州才博医学科技有限公司	一种检测自体cart细胞体液性免疫原性的方法
WO2022221844A2 (en) *	2021-04-13	2022-10-20	WUGEN, Inc.	Improved chimeric antigen receptors and uses thereof
WO2023284875A1 (zh) *	2021-07-16	2023-01-19	克莱格医学有限公司	嵌合抗原受体
CN115466331B (zh) *	2021-11-18	2023-05-30	合源生物科技(天津)有限公司	靶向bcma的嵌合抗原受体及其应用
WO2023098846A1 (zh) *	2021-12-03	2023-06-08	江苏先声药业有限公司	抗bcma纳米抗体及其应用
CN113980907B (zh) *	2021-12-24	2022-03-15	山东兴瑞生物科技有限公司	一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
CA3243771A1 (en) *	2022-02-09	2023-08-17	Hadasit Medical Research Services And Development Ltd.	CAR ANTI-BCMA TO TARGET IMMUNITY-RELATED DISORDERS, COMPOSITIONS AND RELATED METHODS
CN118843693A (zh) *	2022-04-03	2024-10-25	上海先博生物科技有限公司	靶向bcma的嵌合抗原受体及其应用
CN117143248A (zh) *	2022-05-24	2023-12-01	合源康华医药科技(北京)有限公司	靶向bcma-cd19的双特异性嵌合抗原受体及其应用
US12403194B2 (en)	2023-09-25	2025-09-02	Kelonia Therapeutics, Inc.	Compositions for treating cancer
WO2025072257A1 (en) *	2023-09-25	2025-04-03	Kelonia Therapeutics, Inc.	Compositions for treating cancer
US12269882B1 (en)	2023-09-25	2025-04-08	Kelonia Therapeutics, Inc.	Antigen binding polypeptides
WO2025160340A2 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025171383A2 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens and related methods and uses
WO2025171388A1 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens with modified domains and related methods and uses
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
CN118344480A (zh) *	2024-03-19	2024-07-16	浙江康佰裕生物科技有限公司	靶向bcma的单域抗体、嵌合抗原受体及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
ATE68013T1 (de)	1985-07-05	1991-10-15	Whitehead Biomedical Inst	Expression von fremdem genetischem material in epithelzellen.
US4690915A (en)	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
EP0633318A1 (en)	1987-09-11	1995-01-11	Whitehead Institute For Biomedical Research	Transduced fibroblasts and uses therefor
JP2914692B2 (ja)	1987-12-11	1999-07-05	ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ	内皮細胞の遺伝子修飾
DE68927996T2 (de)	1988-02-05	1997-12-04	Hughes Howard Med Inst	Modifizierte hepatozyten und deren anwendung
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
WO1992007573A1 (en)	1990-10-31	1992-05-14	Somatix Therapy Corporation	Genetic modification of endothelial cells
US7175843B2 (en)	1994-06-03	2007-02-13	Genetics Institute, Llc	Methods for selectively stimulating proliferation of T cells
US5827642A (en)	1994-08-31	1998-10-27	Fred Hutchinson Cancer Research Center	Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en)	1995-06-07	2006-06-27	The Regents Of The University Of Michigan	Methods for transfecting T cells
US6692964B1 (en)	1995-05-04	2004-02-17	The United States Of America As Represented By The Secretary Of The Navy	Methods for transfecting T cells
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
JP4787439B2 (ja)	1999-08-17	2011-10-05	バイオジェン・アイデック・エムエイ・インコーポレイテッド	免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
US6797514B2 (en)	2000-02-24	2004-09-28	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US6867041B2 (en)	2000-02-24	2005-03-15	Xcyte Therapies, Inc.	Simultaneous stimulation and concentration of cells
AU4328801A (en)	2000-02-24	2001-09-03	Xcyte Therapies Inc	Simultaneous stimulation and concentration of cells
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
DE10206325A1 (de)	2002-02-14	2003-09-04	Medinnova Ges Med Innovationen	Ummantelter Mikroorganismus
US20030170238A1 (en)	2002-03-07	2003-09-11	Gruenberg Micheal L.	Re-activated T-cells for adoptive immunotherapy
US7261893B2 (en)	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
US7700099B2 (en)	2005-02-14	2010-04-20	Merck & Co., Inc.	Non-immunostimulatory antibody and compositions containing the same
TW200732350A (en)	2005-10-21	2007-09-01	Amgen Inc	Methods for generating monovalent IgG
PL2374818T3 (pl)	2006-06-02	2013-05-31	Regeneron Pharma	Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
SI2406284T1 (sl)	2009-03-10	2017-01-31	Biogen Ma Inc.	Anti-bcma protitelesa
TWI667257B (zh)	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US20130273055A1 (en)	2010-11-16	2013-10-17	Eric Borges	Agents and methods for treating diseases that correlate with bcma expression
TWI807362B (zh)	2010-11-30	2023-07-01	日商中外製藥股份有限公司	細胞傷害誘導治療劑
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh)	2011-03-23	2019-09-06	弗雷德哈钦森癌症研究中心	用于细胞免疫治疗的方法和组合物
US20140105915A1 (en)	2011-05-27	2014-04-17	Glaxo Group Limited	Bcma (cd269/tnfrsf17) - binding proteins
UA112434C2 (uk)	2011-05-27	2016-09-12	Ґлаксо Ґруп Лімітед	Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
DK3473707T3 (da)	2012-05-25	2025-03-17	Cellectis	Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2889764C (en)	2012-11-01	2023-10-10	Martin Lipp	An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh)	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en)	2012-12-07	2016-01-26	Amgen, Inc.	BCMA antigen binding proteins
EP2762496A1 (en)	2013-02-05	2014-08-06	EngMab AG	Method for the selection of antibodies against BCMA
EP2762497A1 (en)	2013-02-05	2014-08-06	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA
JP2016507523A (ja)	2013-02-05	2016-03-10	エンクマフアーゲー	ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
AR095374A1 (es)	2013-03-15	2015-10-14	Amgen Res Munich Gmbh	Moléculas de unión para bcma y cd3
US20180112384A1 (en)	2013-12-30	2018-04-26	Craig Rothleitner	Drainage treatment system
IL303667A (en)	2014-04-30	2023-08-01	Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft	Humanized antibodies against cd269 (bcma)
KR102523934B1 (ko) *	2014-07-24	2023-04-20	2세븐티 바이오, 인코포레이티드	Bcma 키메릭 항원 수용체
EP2982692A1 (en)	2014-08-04	2016-02-10	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA
RS60615B1 (sr)	2014-11-20	2020-08-31	Hoffmann La Roche	Zajednički laki lanci i postupci upotrebe
EP3029068A1 (en)	2014-12-03	2016-06-08	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
HUE053995T2 (hu)	2014-12-05	2021-08-30	Memorial Sloan Kettering Cancer Center	B-sejt-érési antigént célzó antitestek és alkalmazási eljárások
ES2966099T3 (es)	2014-12-05	2024-04-18	Memorial Sloan Kettering Cancer Center	Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos
CA2970466A1 (en)	2014-12-12	2016-06-16	Bluebird Bio, Inc.	Bcma chimeric antigen receptors
RU2706582C2 (ru)	2015-04-13	2019-11-19	Пфайзер Инк.	Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток
MX2017013297A (es)	2015-04-13	2018-06-19	Pfizer	Anticuerpos terapeuticos y sus usos.
WO2016187068A1 (en)	2015-05-15	2016-11-24	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JOP20160154B1 (ar)	2015-07-31	2021-08-17	Regeneron Pharma	أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PT3337824T (pt)	2015-08-17	2020-09-10	Janssen Pharmaceutica Nv	Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
PT3353212T (pt)	2015-09-23	2022-01-05	Regeneron Pharma	Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações
AU2016353067B2 (en)	2015-11-13	2023-10-05	Sanford Research	Anti-BCMA polypeptides and proteins
JP2019505476A (ja)	2015-12-01	2019-02-28	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	組合せ処置およびその方法
JOP20170017B1 (ar)	2016-01-25	2021-08-17	Amgen Res Munich Gmbh	تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
IL313507A (en)	2016-02-03	2024-08-01	Amgen Res Munich Gmbh	Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
HK1259075A1 (zh)	2016-02-17	2019-11-22	Seattle Genetics, Inc.	Bcma抗体和其用以治疗癌症和免疫病症的用途
TWI761831B (zh)	2016-04-01	2022-04-21	美商凱特製藥公司	嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
KR102497013B1 (ko)	2016-06-07	2023-02-20	맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친	Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
WO2018009904A2 (en)	2016-07-08	2018-01-11	Tumeh Paul C	Compositions and treatment methods for cancer immunotherapy
CN114395048B (zh)	2016-09-14	2025-01-28	特纳奥尼股份有限公司	Cd3结合抗体
RS63660B1 (sr)	2016-09-23	2022-11-30	Regeneron Pharma	Anti-muc16 (mucin 16) antitela
WO2018075359A1 (en)	2016-10-18	2018-04-26	Boger Henry William	Wireless power transfer for process control
EP4295918A3 (en)	2016-11-02	2024-03-20	Bristol-Myers Squibb Company	Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018099539A1 (en)	2016-11-29	2018-06-07	Horst Lindhofer	Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CN116284402A (zh)	2016-12-21	2023-06-23	特尼奥生物股份有限公司	仅有重链的抗bcma抗体
CN108341872B (zh)	2017-01-23	2020-05-19	科济生物医药（上海）有限公司	靶向bcma的抗体及其应用
CA3049689A1 (en)	2017-02-06	2018-08-09	Dana-Farber Cancer Institute, Inc.	Compositions and methods for augmenting antibody mediated receptor signaling
WO2018151836A1 (en)	2017-02-17	2018-08-23	Fred Hutchinson Cancer Research Center	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
TWI868050B (zh)	2017-05-05	2025-01-01	美商安進公司	用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
KR102742528B1 (ko)	2017-06-20	2024-12-16	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
IL272304B2 (en)	2017-08-01	2024-10-01	Medimmune Llc	Bcma monoclonal antibody-drug conjugate
JP7137619B2 (ja)	2017-09-29	2022-09-14	モガム・インスティテュート・フォー・バイオメディカル・リサーチ	Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物
PL3694529T3 (pl)	2017-10-13	2024-12-16	Harpoon Therapeutics, Inc.	Trójswoiste białka i sposoby zastosowania
KR102160061B1 (ko) *	2018-02-01	2020-09-29	난징 아이에이에스오 바이오테라퓨틱스 컴퍼니, 리미티드	Bcma에 결합하는 키메릭 항원 수용체(car) 및 그의 용도
SMT202500221T1 (it)	2018-05-24	2025-07-22	Janssen Biotech Inc	Anticorpi anti-cd3 e usi di essi
TWI838389B (zh)	2018-07-19	2024-04-11	美商再生元醫藥公司	雙特異性抗-BCMAｘ抗-CD3抗體及其用途
PH12021552123A1 (en)	2019-03-21	2022-08-22	Regeneron Pharma	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

2019
- 2019-07-18 WO PCT/US2019/042452 patent/WO2020018825A1/en not_active Ceased
- 2019-07-18 DK DK19749097.2T patent/DK3823665T5/da active
- 2019-07-18 SM SM20240102T patent/SMT202400102T1/it unknown
- 2019-07-18 HR HRP20251331TT patent/HRP20251331T1/hr unknown
- 2019-07-18 EP EP19749097.2A patent/EP3823665B1/en active Active
- 2019-07-18 BR BR112021000919-1A patent/BR112021000919A2/pt unknown
- 2019-07-18 CA CA3106612A patent/CA3106612A1/en active Pending
- 2019-07-18 MX MX2021000532A patent/MX2021000532A/es unknown
- 2019-07-18 EA EA202190315A patent/EA202190315A1/ru unknown
- 2019-07-18 FI FIEP19749097.2T patent/FI3823665T3/fi active
- 2019-07-18 FI FIEP23215003.7T patent/FI4324851T3/fi active
- 2019-07-18 SG SG11202100221VA patent/SG11202100221VA/en unknown
- 2019-07-18 RS RS20240417A patent/RS65384B1/sr unknown
- 2019-07-18 PL PL19749097.2T patent/PL3823665T3/pl unknown
- 2019-07-18 US US16/516,060 patent/US12150959B2/en active Active
- 2019-07-18 RS RS20251074A patent/RS67345B1/sr unknown
- 2019-07-18 SI SI201930706T patent/SI3823665T1/sl unknown
- 2019-07-18 ES ES23215003T patent/ES3042810T3/es active Active
- 2019-07-18 JP JP2021502826A patent/JP7404335B2/ja active Active
- 2019-07-18 MY MYPI2021000062A patent/MY207197A/en unknown
- 2019-07-18 HU HUE19749097A patent/HUE066474T2/hu unknown
- 2019-07-18 SM SM20250371T patent/SMT202500371T1/it unknown
- 2019-07-18 MD MDE20210484T patent/MD3823665T2/ro unknown
- 2019-07-18 PT PT197490972T patent/PT3823665T/pt unknown
- 2019-07-18 EP EP23215003.7A patent/EP4324851B1/en active Active
- 2019-07-18 LT LTEPPCT/US2019/042452T patent/LT3823665T/lt unknown
- 2019-07-18 CN CN202510132313.0A patent/CN119954969A/zh active Pending
- 2019-07-18 HR HRP20240494TT patent/HRP20240494T1/hr unknown
- 2019-07-18 DK DK23215003.7T patent/DK4324851T3/da active
- 2019-07-18 CN CN201980048197.7A patent/CN112437671B/zh active Active
- 2019-07-18 AU AU2019308290A patent/AU2019308290B2/en active Active
- 2019-07-18 PT PT232150037T patent/PT4324851T/pt unknown
- 2019-07-18 ES ES19749097T patent/ES2973946T3/es active Active
- 2019-07-18 LT LTEP23215003.7T patent/LT4324851T/lt unknown
- 2019-07-18 MA MA65527A patent/MA65527B1/fr unknown
2021
- 2021-01-06 IL IL279979A patent/IL279979A/en unknown
- 2021-01-07 ZA ZA2021/00107A patent/ZA202100107B/en unknown
- 2021-01-07 PH PH12021550036A patent/PH12021550036A1/en unknown
- 2021-01-14 MX MX2025004599A patent/MX2025004599A/es unknown
- 2021-01-14 MX MX2025004598A patent/MX2025004598A/es unknown
- 2021-01-15 CO CONC2021/0000334A patent/CO2021000334A2/es unknown
- 2021-01-18 CL CL2021000142A patent/CL2021000142A1/es unknown
2022
- 2022-12-28 CL CL2022003796A patent/CL2022003796A1/es unknown
2023
- 2023-12-12 JP JP2023208956A patent/JP7601998B2/ja active Active
2024
- 2024-05-21 US US18/670,684 patent/US20240325445A1/en active Pending

Also Published As

Publication number	Publication date
JP2021531004A (ja)	2021-11-18
JP7404335B2 (ja)	2023-12-25
ES3042810T3 (en)	2025-11-24
RS67345B1 (sr)	2025-11-28
CO2021000334A2 (es)	2021-01-29
DK4324851T3 (da)	2025-10-06
MX2025004598A (es)	2025-05-02
MA65527B1 (fr)	2024-05-31
US20200023010A1 (en)	2020-01-23
ES2973946T3 (es)	2024-06-25
US12150959B2 (en)	2024-11-26
LT3823665T (lt)	2024-02-26
DK3823665T5 (da)	2024-08-19
US20240325445A1 (en)	2024-10-03
IL279979A (en)	2021-03-01
CA3106612A1 (en)	2020-01-23
CN119954969A (zh)	2025-05-09
MY207197A (en)	2025-02-05
AU2019308290B2 (en)	2025-10-16
AU2019308290A1 (en)	2021-02-18
MD3823665T2 (ro)	2024-05-31
FI4324851T3 (fi)	2025-10-08
PT4324851T (pt)	2025-09-23
SMT202400102T1 (it)	2024-05-14
JP2024028944A (ja)	2024-03-05
SG11202100221VA (en)	2021-02-25
EP3823665A1 (en)	2021-05-26
FI3823665T3 (fi)	2024-03-01
PH12021550036A1 (en)	2021-09-20
CN112437671A (zh)	2021-03-02
CL2021000142A1 (es)	2021-07-02
SI3823665T1 (sl)	2024-03-29
PT3823665T (pt)	2024-02-26
EP4324851A2 (en)	2024-02-21
HRP20251331T1 (hr)	2025-12-05
KR20210035832A (ko)	2021-04-01
PL3823665T3 (pl)	2024-06-03
EA202190315A1 (ru)	2021-04-16
EP3823665B1 (en)	2024-01-24
CL2022003796A1 (es)	2023-07-07
RS65384B1 (sr)	2024-04-30
CN112437671B (zh)	2025-02-25
EP4324851B1 (en)	2025-08-27
MX2021000532A (es)	2021-04-12
WO2020018825A1 (en)	2020-01-23
MX2025004599A (es)	2025-05-02
ZA202100107B (en)	2024-07-31
BR112021000919A2 (pt)	2021-04-27
HRP20240494T1 (hr)	2024-07-05
JP7601998B2 (ja)	2024-12-17
EP4324851A3 (en)	2024-05-15
SMT202500371T1 (it)	2025-11-10
DK3823665T3 (da)	2024-03-04
LT4324851T (lt)	2025-10-10

Publication	Publication Date	Title
HUE066474T2 (hu)	2024-08-28	BCMA-specifitással rendelkezõ kiméra antigénreceptorok és azok alkalmazása
IL280029A (en)	2021-03-01	Ror-1 specific chimeric antigen receptors and uses thereof
IL279367A (en)	2021-01-31	BCMA chimeric antigen receptors and their uses
PT3802608T (pt)	2025-06-27	Anticorpos anti-cd3 e utilizações destes
EP3759143A4 (en)	2022-03-02	ANTI-TIGIT ANTIBODIES AND THEIR USES
EP3740224A4 (en)	2022-05-04	ANTI-LILRB ANTIBODIES AND THEIR USES
EP3999550A4 (en)	2023-09-06	ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
EP3658163A4 (en)	2021-08-04	IMPROVED ANTIGENIC CHEMICAL RECEPTORS AND THEIR USES
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
HUE062927T2 (hu)	2023-12-28	Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
IL289354A (en)	2022-02-01	Anti-cd154 antibodies and uses thereof
PL3436079T3 (pl)	2021-12-20	Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
EP3365364A4 (en)	2019-08-07	Antibody/t-cell receptor chimeric constructs and uses thereof
EP3735427A4 (en)	2021-09-15	ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
EP3630980A4 (en)	2021-03-10	CELL PREPARATION OF CHEMERICAL ANTIGENIC RECEPTORS AND USES OF THE SAME
IL281428A (en)	2021-04-29	Chimeric antigen receptor
EP3904382A4 (en)	2022-07-13	ANTI-IL-23P19 ANTIBODIES AND ITS USES
IL285909A (en)	2021-10-31	Anti-bcma chimeric antigen receptors
IL286984A (en)	2021-12-01	Humanized anti-dll3 chimeric antigen receptors and uses thereof
HUE046749T2 (hu)	2020-03-30	Antigénreceptorok és azok felhasználása
EP3790586A4 (en)	2022-01-19	Anti-dll3 antibodies and uses thereof
IL281297A (en)	2021-04-29	Anti-npr1 antibodies and uses thereof
EP3802615A4 (en)	2022-04-13	Muc16 specific chimeric antigen receptors and uses thereof
HUE063621T2 (hu)	2024-01-28	ß-interferon elleni ellenanyagok és alkalmazásuk
EP3894440A4 (en)	2022-09-07	ANTI-IL-27 ANTIBODIES AND THEIR USES